DPP4 and steatosis: Inhibitors of the exopeptidase dipeptidyl‐peptidase 4 (DPP4) are anti‐diabetes drugs and have been shown to reduce steatosis in MASLD patients (Androutsakos et al, 2022), though failing to consistently ameliorate liver inflammation and fibrosis in larger meta‐analyses (Dos Santos et al, 2021).